Advanced genetic screening of embryos to improve IVF success rates and support healthy pregnancies
PGT is a state-of-the-art genetic testing procedure performed on embryos during IVF to identify genetic abnormalities before implantation.
A few cells are safely removed from the embryo at the blastocyst stage (5-7 days after fertilisation).
Cells are analysed using advanced genomic technologies to detect chromosomal abnormalities and genetic mutations.
Based on genetic results, embryos with the highest chance of leading to a healthy pregnancy are selected for transfer.
Comprehensive testing solutions tailored to your specific needs
Detects chromosomal number abnormalities (aneuploidies) such as Down syndrome, Turner syndrome, and others.
Advanced maternal age (≥35), recurrent pregnancy loss, multiple IVF failures
PGT-A+ is our advanced, enhanced version providing additional layers of analysis including:
Advanced maternal age, recurrent pregnancy loss, multiple IVF failures
Screens for specific inherited single-gene disorders such as cystic fibrosis, sickle cell anemia, and Huntington's disease.
Couples with known genetic disorders, family history of hereditary conditions
Identifies embryos with balanced or unbalanced chromosomal structural rearrangements (translocations, inversions).
Known chromosomal rearrangement carriers, recurrent miscarriage due to chromosomal issues
Specialised procedure that allows selection of embryos that are both genetically healthy and HLA-compatible with an existing sibling.
Families requiring HLA-matched, genetically normal embryos
Cutting-edge genetic assessment performed at the earliest stage of embryonic development before the first cell division.
0 PN, 1PN or PN3 embryos
How genetic testing enhances your IVF journey
Selecting genetically normal embryos increases implantation rates by up to 70% and reduces time to pregnancy.
Chromosomal abnormalities cause 60-70% of miscarriages. PGT-A reduces this risk by selecting chromosomally normal embryos.
With confidence in embryo viability, single embryo transfer becomes safer, reducing risks of multiple pregnancies.
PGT-M allows families with hereditary conditions to have biological children free from specific genetic diseases.
PGT may be recommended for couples facing specific challenges in their fertility journey:
Utilizing cutting-edge genomic platforms for accurate results
High-resolution comprehensive chromosome screening with >99% accuracy for aneuploidy detection.
Advanced SNP-based technology for PGT-M that doesn't require family-specific test development.
Chromosomal microarray analysis for detecting submicroscopic deletions and duplications.
Turnaround Time: 7-10 days for PGT-A, 2-4 weeks for PGT-M (including test design)
Accuracy: >99% for chromosome-level abnormalities, >98% for single-gene disorders
Common questions about Preimplantation Genetic Testing
Yes, embryo biopsy at the blastocyst stage is a well-established procedure with minimal risk. Studies show no increased risk of birth defects or developmental issues in babies born from PGT-tested embryos.
PGT-A has >99% accuracy for detecting chromosomal abnormalities. PGT-M accuracy is >98% for single-gene disorders. All positive results are confirmed with prenatal testing.
While PGT significantly improves success rates, it doesn't guarantee pregnancy. Other factors like uterine receptivity and embryo quality also play important roles.
PGT-M can test for any single-gene disorder where the genetic mutation is known. PGT-A screens for chromosomal abnormalities but not single-gene disorders unless specifically tested.
Our team of board-certified genetic counselors and reproductive specialists are here to guide you through every step of the PGT process.
All consultations include a review of your medical history and personalized testing recommendations.